A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Paclitaxel (Primary) ; Relacorilant (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ROSELLA
- Sponsors Corcept Therapeutics
- 05 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
- 08 Apr 2024 According to a Corcept Therapeutics media release, company expects progression-free survival data, ROSELLA's primary endpoint, by the end of this year.
- 08 Apr 2024 Status changed from recruiting to active, no longer recruiting, according to a Corcept Therapeutics media release.